ASCO 2020: Breast cancer roundup
ASCO 2020: Breast cancer roundup
The PANDA study: Combining panitumumab with FOLFOX or 5FU in elderly patients with RAS-BRAF WT metastatic colorectal cancer
Comparing pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk MDS/CMML or low-blast AML
COVID-19: Optimising supportive care during active cancer treatment
Perioperative novel systemic immunotherapy-based approaches in urinary cancers
ASCO 2020: Updates in renal cancer
TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to monochemotherapy
KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H/dMMR colorectal cancer
Highlights from ASCO 2020
PARP inhibitors in prostate cancer: Guidelines, who to test and the patient pathway
CheckMate 227 three-year update: Nivolumab plus ipilimumab versus chemo as first-line treatment for advanced NSCLC
ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer